Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors (ETOILE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02838602
Recruitment Status : Recruiting
First Posted : July 20, 2016
Last Update Posted : March 7, 2018
Information provided by (Responsible Party):
Hospices Civils de Lyon

July 18, 2016
July 20, 2016
March 7, 2018
December 23, 2017
November 2023   (Final data collection date for primary outcome measure)
Progression free survival (PFS) [ Time Frame: up to 5 years or loss of follow-up ]
Starting point for PFS measurement is the randomization date
Same as current
Complete list of historical versions of study NCT02838602 on Archive Site
  • Grades of the CTCAE-V4.02 classification [ Time Frame: up to 5 years or loss of follow-up ]
  • EQ-5D questionnaire [ Time Frame: up to 5 years or loss of follow-up ]
    Quality of life
  • Local progression free survival [ Time Frame: up to 5 years or loss of follow-up ]
    takes account of the local progression of the tumor in the planning target volume (PTV)
  • Metastases free survival [ Time Frame: up to 5 years or loss of follow-up ]
    takes account of any site of relapse outside of the PTV
  • Overall survival [ Time Frame: up to 5 years or loss of follow-up ]
    delay of death of any cause accounted starting from randomization
Same as current
Not Provided
Not Provided
Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors
Transnational Randomized Study Comparing Carbon Ions Therapy Versus Conventional Radiotherapy - Including Protontherapy - for the Treatment of Radioresistant Tumors
This is a transnational prospective randomized trial comparing definitive carbon ion therapy versus photon or combined photon and protontherapy as standard treatment for unresectable or macroscopically uncompleted resected radioresistant tumors. Eligible tumors are axial chordoma (except of base of skull), adenoid cystic carcinoma of head and neck (except of trachea) and sarcomas of any site (except chondrosarcoma of the skull base), non previously irradiated and without pre-planned surgery or chemotherapy after the clinical trial procedure. Randomization is balanced 1 for 1. Patients of the experimental arm are treated in carbon ions centers in Europe and patients of the standard arm are treated in France in their closest participating radiotherapy center. An accrual of 250 patients is needed and an absolute difference of 20% of relapse free survival at five years is awaited. The main endpoint is the progression free survival at five years. The trial is supported by the French program of clinical research and the national health insurance. Two associated studies are carried out: a radiobiological one looking for radioresistance markers in the sarcomas biopsies, and the second one is about medico economics.
Not Provided
Not Applicable
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma
  • Radiation: Carbon ions therapy
    External radiotherapy by accelerated carbon nucleus in a specialized hadrontherapy center
  • Radiation: Advanced external radiotherapy by Xrays or protons
    Radiotherapy by any appropriate advance procedure of photontherapy (IMRT, Volumetric Modulated Arc Therapy (VMAT), Tomo, etc.) or when possible by protontherapy or even a combination of both types of radiotherapy
  • Experimental: Carbon ions therapy
    Radical and exclusive carbon ions radiotherapy
    Intervention: Radiation: Carbon ions therapy
  • Active Comparator: Conventional radiotherapy
    Radical radiotherapy by Xrays and / or protons
    Intervention: Radiation: Advanced external radiotherapy by Xrays or protons
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
May 2024
November 2023   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • age ≥ 18 years
  • No severe comorbidity, life expectancy above 10 years
  • Unresectable or inoperable or R2 resection of the tumor
  • Radioresistant tumor according to the limitative list as following:

    • adenoid cystic carcinoma of head and neck (larynx and trachea excluded)
    • soft tissue sarcoma
    • rhabdomyosarcoma
    • retroperitoneal sarcoma
    • osteosarcoma (Ewing excluded)
    • chondrosarcoma (except of skull base)
    • axial skeleton chordoma (except of skull base)
    • angiosarcoma
  • No skin involvement
  • ECOG Performance Status ≤ 2 or Karnovsky index ≥ 60
  • no pregnancy of possibility of pregnancy during the treatment
  • having an health insurance
  • signature of a written informed consent
  • validation of the randomization criteria: namely, a carbon ions therapy indication assessed by the medical team of a hadrontherapy center and able to by treated within two month from registration.

Exclusion Criteria:

  • previous irradiation in of the same tumor site
  • active metastatic disease
  • any contra-indication to undergo a radiation therapy by Xray or particle therapy
  • planned surgery or chemotherapy to take place after completion of radiotherapy
  • removable metallic material in the planning target volume
  • any history of another cancer in remission since less than 5 years (except in situ cervix carcinoma of basocellular skin cancer treated in a curative manner)
  • impossible follow-up.
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact: Pascal Pommier, MD (0)4 78 78 51 66 ext +33
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Not Provided
Hospices Civils de Lyon
Hospices Civils de Lyon
Not Provided
Principal Investigator: Pascal Pommier, MD Centre Leon Berard
Hospices Civils de Lyon
March 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP